Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 May 2023 | Story Andre Damons | Photo Supplied
Prof Matsabisa Motlalepula
Prof Matsabisa Motlalepula, an African traditional medicine expert from the University of the Free State (UFS), will attend the first WHO Traditional Medicine Global Summit in India in August.

Prof Matsabisa Motlalepula, an African traditional medicine expert from the University of the Free State (UFS), will attend the first World Health Organisation (WHO) Traditional Medicine Global Summit in India in August after being invited to serve as a member of the Summit External Advisory Group for the WHO Traditional Medicine Global Summit (“Advisory Group”).

As chairperson of the WHO Regional Expert Advisory Committee on Traditional Medicine (REACT), Prof Motlalepula, the Director of the UFS Department of Pharmacology, has been nominated to serve as the Global Summit Advisory Group expert from the WHO to provide advice on themes, content, and format of sessions, and to provide reviews and recommendations to the Summit session coordinators and speakers at the Summit.

Summit will highlight success stories

The Advisory Group is comprised of nine members nominated across the six WHO regions and globally, with recognised expertise in traditional medicines as well as expertise on the Summit focus areas that include leadership and partnership, evidence and learning, data and regulation, biodiversity and sustainability, innovation and technology.

WHO will hold its Traditional Medicine Global Summit from August 17-18, 2023, in Gandhinagar, Gujarat, India, alongside the G20 health ministerial meeting. The Summit will be organised by the WHO Global Centre for Traditional Medicine collaborating closely with all WHO major offices. 

The Summit will highlight success stories in countries using traditional medicine across universal health coverage, the Sustainable Development Goals (SDGs), and Health for All. It will showcase game-changing advances in evidence, data, biodiversity and innovations that enable the safe, effective and equitable use of traditional medicine. The Summit will be a platform for all stakeholders of traditional medicine, including policymakers, practitioners, academics, private sector, civil society, community representatives, and others will discuss health and traditional medicines issues.

“It is always an honour and privilege for me to be asked to avail myself to the activities of such high-level United Nations bodies. I am humbled to be identified and nominated by WHO to be amongst the nine experts in the six WHO regions and globally. 

“I am very honoured and will do my utmost to deliver on the global mandate as well as stick to the terms of reference of my appointment to such a prestigious global summit. This shows the trust the WHO has in my capabilities, and this is good for the institution, the continent as well as the traditional health practitioners and scientists in this field of research,” says Prof Motlalepula. 

Endorsing well-researched traditional medicines

He says each time he sees the involvement of Africa in these international gatherings on traditional medicines, it marks another step toward the institutionalisation and global acceptance of African traditional medicines and medical practices in health systems. It further shows the growing role UFS is beginning to play in the global arena around traditional medicines.

According to him, he will, as always, push for WHO to be an example in support of traditional medicines and the participation of traditional health practitioners in its activities.

“I would seek from WHO to look into endorsing well-researched traditional medicine products and making them available in our health systems. Secondly, making recommendations for review of medicines regulatory authorities to reform and look favourably at traditional medicines product registration systems. I would advise on supporting continuous research into traditional medicines but more importantly for those products to be registered and put on the market.”

Prof Motlalepula says he has a few expectations, always working hard, dedicating his time and efforts to delivering what is expected, being part of a team and contributing to the overall team efforts. He expects positive resolutions moving forward the development and institutionalisation of traditional medicines, as well as a commitment to see the acceptance that the contribution of traditional medicines plays in the well-being of people and its formal contributions to universal health coverage and SDGs acknowledged. 

“I expect to hear about improved financial and political support for research and fast-tracking the manufacturing of well-researched, quality, safe and effective traditional medicines and their inclusion in national health systems. I expect to hear talk about integrated health that incorporates the application of traditional medicines in national health systems. I expect indeed a few positive things around the development of traditional medicine and serious commitment to supporting it.

“Given the scope of the work of the Advisory Group, it is very clear that the work is huge for the organisation, but I am ready for this,” says Prof Motlalepula.

The scope of work for the Advisory Group has been prepared and includes: 

  • Providing expert advice to WHO on the technical content and format of the sessions and exhibition for the WHO Traditional Medicine Global Summit;
  • Agreeing on technical review criteria with respect to thematic coherence across the Summit, strength of evidence and data, methodologies, global relevance and other considerations; 
  • Reviewing the proposed content of the Summit sessions and exhibitions using the technical review criteria and providing expert recommendations to ensure high-quality sessions;
  • Advising on the development of a journal series of papers related to the Global Summit using the agreed technical criteria to select the papers;
  • Providing expert inputs to Summit organisation meetings and multistakeholder consultations, as agreed with WHO;
  • Developing and sharing recommendations of the Summit advisory group with WHO and partners in a timely manner to inform the organisation of the Summit, as appropriate in alignment with the WHO conflict-of-interest declaration and Framework for Engagement with Non-State Actors (FENSA); and 
  • Developing an Advisory Group report advising WHO on key lessons and priority actions following the first WHO Traditional Medicine Global Summit.

News Archive

Inaugural lecture: Prof Robert Bragg, Dept. of Microbial, Biochemical and Food Biotechnology
2006-05-17



Attending the inaugural lecture were in front from the left Prof Robert Bragg (lecturer at the Department of Microbial, Biochemical and Food Biotechnology) and Frederick Fourie (Rector and Vice-Chancellor).  At the back from the left were Prof James du Preez (Departmental Chairperson:  Department of Microbial, Biochemical and Food Biotechnology) and Prof Herman van Schalkwyk (Dean: Faculty of Natural and Agricultural Sciences). Photo: Stephen Collett
 

A summary of an inaugural lecture delivered by Prof Robert Bragg at the University of the Free State:

CONTROL OF INFECTIOUS AVIAN DISEASES – LESSONS FOR MAN?

Prof Robert R Bragg
Department of Microbial, Biochemical and Food Biotechnology
University of the Free State

“Many of the lessons learnt in disease control in poultry will have application on human medicine,” said Prof Robert Bragg, lecturer at the University of the Free State’s (UFS) Department of Microbial, Biochemical and Food Biotechnology during his inaugural lecture.

Prof Bragg said the development of vaccines remains the main stay of disease control in humans as well as in avian species.  Disease control can not rely on vaccination alone and other disease-control options must be examined.  

“With the increasing problems of antibiotic resistance, the use of disinfection and bio security are becoming more important,” he said.

“Avian influenza (AI) is an example of a disease which can spread from birds to humans.  Hopefully this virus will not develop human to human transmission,” said Prof Bragg.

According to Prof Bragg, South Africa is not on the migration route of water birds, which are the main transmitters of AI.  “This makes South Africa one of the countries less likely to get the disease,” he said.

If the AI virus does develop human to human transmission, it could make the 1918 flu pandemic pale into insignificance.  During the 1918 flu pandemic, the virus had a mortality rate of only 3%, yet more than 50 million people died.

Although the AI virus has not developed human-to-human transmission, all human cases have been related to direct contact with infected birds. The mortality rate in humans who have contracted this virus is 67%.

“Apart from the obvious fears for the human population, this virus is a very serious poultry pathogen and can cause 100% mortality in poultry populations.  Poultry meat and egg production is the staple protein source in most countries around the world. The virus is currently devastating the poultry industry world-wide,” said Prof Bragg.

Prof Bragg’s research activities on avian diseases started off with the investigation of diseases in poultry.  “The average life cycle of a broiler chicken is 42 days.  After this short time, they are slaughtered.  As a result of the short generation time in poultry, one can observe changes in microbial populations as a result of the use of vaccines, antibiotics and disinfectants,” said Prof Bragg.   

“Much of my research effort has been directed towards the control of infectious coryza in layers, which is caused by the bacterium Avibacterium paragallinarum.  This disease is a type of sinusitis in the layer chickens and can cause a drop in egg product of up to 40%,” said Prof Bragg.

The vaccines used around the world in an attempt to control this disease are all inactivated vaccines. One of the most important points is the selection of the correct strains of the bacterium to use in the vaccine.

Prof Bragg established that in South Africa, there are four different serovars of the bacterium and one of these, the serovar C-3 strain, was believed to be unique to Southern Africa. He also recently discovered this serovar for the first time in Israel, thus indicating that this serovar might have a wider distribution than originally believed.

Vaccines used in this country did not contain this serovar.  Prof Bragg established that the long term use of vaccines not containing the local South African strain resulted in a shift in the population distribution of the pathogen.

Prof Bragg’s research activities also include disease control in parrots and pigeons.   “One of the main research projects in my group is on the disease in parrots caused by the circovirus Beak and Feather Disease virus. This virus causes serious problems in the parrot breeding industry in this country. This virus is also threatening the highly endangered and endemic Cape Parrot,” said Prof Bragg.

Prof Bragg’s research group is currently working on the development of a DNA vaccine which will assist in the control of the disease, not only in the parrot breeding industry, but also to help the highly endangered Cape Parrot in its battle for survival.

“Not all of our research efforts are directed towards infectious coryza or the Beak and Feather Disease virus.  One of my Masters students is currently investigating the cell receptors involved in the binding of Newcastle Disease virus to cancerous cells and normal cells of humans. This work will also eventually lead to a possible treatment of cancer in humans and will assist with the development of a recombinant vaccine for Newcastle disease virus,” said Prof Bragg.

We are also currently investigating an “unknown” virus which causes disease problems in poultry in the Western Cape,” said Prof Bragg.
 
“Although disinfection has been extensively used in the poultry industry, it has only been done at the pre-placement stage. In other words, disinfectants are used before the birds are placed into the house. Once the birds are placed, all use of disinfectants stops,” said Prof Bragg.

“Disinfection and bio security can be seen as the ‘Cinderella’ of disease control in poultry.  This is also true for human medicine. One just has to look at the high numbers of people who die from hospital-acquired infections to realise that disinfection is not a concept which is really clear in human health care,” said Prof Bragg.

Much research has been done in the control of diseases through vaccination and through the use of antibiotics. “These pillars of disease control are, however, starting to crumble and more effort is needed on disinfection and bio security,” said Prof Bragg.

Prof Bragg has been working in close co-operation with a chemical manufacturing company in Stellenbosch to develop a unique disinfectant which his highly effective yet not toxic to the birds.

As a result of this unique product, he has developed the continual disinfection program for use in poultry. In this program the disinfectant is used throughout the production cycle of the birds. It is also used to ensure that there is excellent pre-placement disinfection.

“The program is extensively used for the control of infectious diseases in the parrot-breeding industry in South Africa and the product has been registered in 15 countries around the world with registration in the USA in the final process,” said Prof Bragg.

“Although the problem of plasmid mediated resistance to disinfectants is starting to rear its ugly head, this has allowed for the opening of a new research field which my group will hopefully exploit in the near future,” he said.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept